IP Library Granted Patent US 7,935,704
Granted Patent B2
US 7,935,704 · App. 11/051,268 · Granted May 3, 2011

Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Assignee: Nereus Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,704
App. No.
11/051,268
Granted
May 3, 2011
Kind
B2
Abstract

Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R 1 , R 1 ′, R 1 ″, R 2 , R 3 , R 4 , R 5 , and R 6 , X 1 and X 2 , Y, Z, Z 1 , Z 2 , Z 3 , and Z 4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.

Claims (23)

1. A method for treating a condition in an animal, comprising administering to the animal a compound in an amount that is effective to reduce vascular proliferation or in an amount that is effective to reduce vascular density, wherein the condition is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, melanoma, angiofibroma, Kaposi sarcoma, hemangioma, acoustic neuroma, and neurofibroma, wherein the compound has the structure of Formula (I)

wherein

R 1 is selected from the group consisting of a hydrogen atom, a halogen atom, hydroxy, and cyano, or selected from the group consisting of saturated C 1 - C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, amino, nitro, azido, phenyl, carboxy, —CO—O—R 7 , alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CCO—R 7 , each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO 2 -alkyl, and —SO 2 -aryl;

R 7 is selected from a hydrogen atom or a halogen atom or selected from the group consisting of saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, amino, substituted amino, nitro, azido, and phenyl groups, each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO 2 -alkyl, and —SO 2 -aryl;

R 4 is a branched alkyl or branched alkenyl group;

R 1 ′ and R 1 ″ are each independently selected from the group consisting of a hydrogen atom, a halogen atom, hydroxy, and cyano, or independently selected from the group consisting of saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, amino, nitro, azido, phenyl, carboxy, —CO—O—R 7 , alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CCO—R 7 , each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO- aryl, —SO 2 -alkyl, and —SO 2 -aryl;

R, R 1 ′ and R 1 ″ are either covalently bound to one another or are not covalently bound to one another;

R 2 , R 3 , R 5 , and R 6 are hydrogen;

X 1 and X 2 are oxygen;

Y is a nitrogen atom;

n is an integer equal to one;

Z, Z 1 , Z 2 , Z 3 and Z 4 are each a carbon atom; and

the dashed bonds may be either single or double bonds.

2. The method of claim 1 , wherein said animal is a human.

3. The method of claim 1 , wherein the compound is

4. The method of claim 1 , wherein

R 1 is selected from the group consisting of a hydrogen atom, a halogen atom, hydroxy, and cyano, or selected from the group consisting of saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, alkoxy, aryl, amino, azido, phenyl, carboxy, —CO—O—R 7 , alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CCO—R 7 , each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO 2 -alkyl, and —SO 2 -aryl; and

R 1 ′ and R 1 ″ are each independently selected from the group consisting of a hydrogen atom, a halogen atom, hydroxy, and cyano, or independently selected from the group consisting of saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, alkoxy, aryl, amino, nitro, azido, phenyl, carboxy, —CO—O—R 7 , alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CCO—R 7 , each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO- aryl, —SO 2 -alkyl, and —SO 2 -aryl.

5. The method of claim 1 , wherein

R 1 is selected from the group consisting of a hydrogen atom, a halogen atom, hydroxy, and cyano, or selected from the group consisting of saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, alkoxy, aryl, amino, azido, phenyl, carboxy, —CO—O—R 7 , alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl —CCO—R 7 , each optionally substituted with one or more of alkoxy, cycloalkyl, cycloalkenyl, acyl, aclyamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxy, carboxy, carboxyalkyl, aryl, arlyoxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO 2 -alkyl, and —SO 2 -aryl; and

R 1 ′ and R 1 ″ are hydrogen.

6. The method of claim 1 , wherein R 4 is tert-butyl.

7. The method of claim 1 , wherein R 4 is 2-methyl-butenyl.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2014
From: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
To: BEYONDSPRING PHARMACEUTICALS, INC.
Reel/Frame 033519/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2013
From: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
To: BEYONDSPRING PHARMACEUTICALS, INC.
Reel/Frame 030723/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2013
From: NEREUS PHARMACEUTICALS, INC.
To: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.
Reel/Frame 030715/0457 →
SECURITY AGREEMENT Recorded May 21, 2009
From: NEREUS PHARMACEUTICALS, INC.
To: HBM BIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
Reel/Frame 022719/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2005
From: PALLADINO, MICHAEL A.; LLOYD, GEORGE KENNETH; HAYASHI, YOSHIO; NICHOLSON, BENJAMIN
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 016210/0627 →
Continuity (4)
Continuation In Part 10632531 · Aug 1, 2003
Provisional Application 60542073 · Feb 4, 2004
Provisional Application 60624262 · Nov 1, 2004
Related Publication 20050197344A1 · Sep 8, 2005